{"id":"oral-casopitant-gw679769","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1672054","moleculeType":"Small molecule","molecularWeight":"616.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Casopitant selectively antagonizes the NK1 receptor, which is a key mediator of nausea and vomiting signals in the central nervous system. By blocking substance P binding to NK1 receptors in brain regions controlling emesis, it prevents both acute and delayed chemotherapy-induced nausea and vomiting (CINV). This mechanism complements 5-HT3 antagonists and corticosteroids used in standard antiemetic regimens.","oneSentence":"Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:36.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT00334646","phase":"PHASE1","title":"Cyclophosphamide Drug Interaction Study In Cancer Patients","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2005-08-10","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":25},{"nctId":"NCT00437229","phase":"PHASE1","title":"A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-19","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":37},{"nctId":"NCT00359177","phase":"PHASE1","title":"Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12-01","conditions":"Vomiting","enrollment":24},{"nctId":"NCT00405080","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-11","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":12},{"nctId":"NCT00404378","phase":"PHASE1","title":"Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-20","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":15},{"nctId":"NCT00431236","phase":"PHASE3","title":"A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-06","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":810},{"nctId":"NCT00404274","phase":"PHASE1","title":"A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-01","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":97},{"nctId":"NCT00358813","phase":"PHASE1","title":"Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-08","conditions":"Vomiting","enrollment":18},{"nctId":"NCT00511823","phase":"PHASE1","title":"The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-23","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":16},{"nctId":"NCT00460707","phase":"PHASE1","title":"A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-16","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":85},{"nctId":"NCT00358410","phase":"PHASE2","title":"An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01","conditions":"Nonulcer Dyspepsia","enrollment":13},{"nctId":"NCT00108095","phase":"PHASE2","title":"A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative","enrollment":701},{"nctId":"NCT00321477","phase":"PHASE2","title":"A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12","conditions":"Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder","enrollment":160},{"nctId":"NCT00274690","phase":"PHASE2","title":"Post-Operative Nausea And Vomiting Study In Female Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative","enrollment":435},{"nctId":"NCT00326248","phase":"PHASE3","title":"Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Nausea and Vomiting, Postoperative","enrollment":482},{"nctId":"NCT00891761","phase":"PHASE3","title":"A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2009-09","conditions":"Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting","enrollment":""},{"nctId":"NCT00104403","phase":"PHASE2","title":"Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting","enrollment":722},{"nctId":"NCT00366834","phase":"PHASE3","title":"Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-07","conditions":"Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced","enrollment":1840}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oral Casopitant (GW679769)","genericName":"Oral Casopitant (GW679769)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}